Stonepine Capital Management LLC Purchases New Shares in Oruka Therapeutics, Inc. $ORKA

Stonepine Capital Management LLC acquired a new stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 7,500 shares of the company’s stock, valued at approximately $713,775,000.

Other large investors have also recently added to or reduced their stakes in the company. Algert Global LLC lifted its holdings in shares of Oruka Therapeutics by 3.5% during the second quarter. Algert Global LLC now owns 5,380 shares of the company’s stock worth $512,000 after buying an additional 180 shares in the last quarter. Royal Bank of Canada boosted its position in shares of Oruka Therapeutics by 47.2% in the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock valued at $34,000 after acquiring an additional 365 shares during the period. Kennedy Capital Management LLC grew its stake in shares of Oruka Therapeutics by 0.9% in the fourth quarter. Kennedy Capital Management LLC now owns 48,686 shares of the company’s stock valued at $1,476,000 after acquiring an additional 420 shares in the last quarter. AlphaCentric Advisors LLC grew its stake in shares of Oruka Therapeutics by 5.8% in the first quarter. AlphaCentric Advisors LLC now owns 11,506 shares of the company’s stock valued at $564,000 after acquiring an additional 626 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its position in Oruka Therapeutics by 35.0% during the fourth quarter. Russell Investments Group Ltd. now owns 3,041 shares of the company’s stock worth $92,000 after acquiring an additional 788 shares during the period. Institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Stock Performance

Shares of NASDAQ ORKA opened at $96.54 on Friday. Oruka Therapeutics, Inc. has a 52 week low of $14.61 and a 52 week high of $115.51. The stock has a market capitalization of $6.39 billion, a P/E ratio of -47.56 and a beta of -0.34. The stock’s fifty day moving average is $94.23 and its 200 day moving average is $67.34.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). Equities research analysts forecast that Oruka Therapeutics, Inc. will post -2.27 earnings per share for the current year.

Insider Activity

In other news, Director Carl Dambkowski sold 22,417 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $70.13, for a total transaction of $1,572,104.21. Following the completion of the sale, the director owned 51,326 shares of the company’s stock, valued at approximately $3,599,492.38. This represents a 30.40% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Arjun Agarwal sold 10,000 shares of the stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $106.66, for a total transaction of $1,066,600.00. Following the sale, the senior vice president owned 15,312 shares in the company, valued at $1,633,177.92. This represents a 39.51% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 83,116 shares of company stock valued at $6,636,533 in the last 90 days. 23.49% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several analysts have weighed in on ORKA shares. Wall Street Zen cut shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. Leerink Partners set a $120.00 target price on shares of Oruka Therapeutics in a research report on Thursday, April 30th. Guggenheim reaffirmed a “buy” rating and set a $200.00 target price on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Wedbush reiterated an “outperform” rating and issued a $165.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Finally, BTIG Research reiterated a “buy” rating and issued a $151.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Oruka Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $134.30.

Oruka Therapeutics Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.